You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)

Article metrics

Article menu

Download PDFPDF

Poster Presentation
Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)
Free

 

Online download statistics by month:

Online download statistics by month: January 2020 to August 2024

AbstractFullPdf
Jan 2020010
Feb 2020010
Mar 2020040
Apr 2020010
Jun 20200130
Jul 2020040
Sep 2020050
Oct 2020020
Nov 2020020
Dec 2020021
Jan 2021031
Feb 2021031
Mar 2021042
Apr 2021040
May 2021010
Jun 2021010
Jul 2021030
Aug 2021001
Sep 2021040
Oct 2021050
Nov 2021033
Dec 2021041
Jan 2022030
Feb 2022010
Mar 2022010
Apr 2022020
May 2022051
Jun 2022041
Jul 2022022
Aug 2022075
Sep 2022042
Oct 2022012
Nov 2022030
Dec 2022050
Jan 2023051
Feb 2023040
Mar 2023010
May 2023010
Jun 2023031
Jul 2023021
Sep 2023041
Oct 2023011
Nov 2023010
Dec 20230102
Jan 2024010
Feb 2024080
Mar 20240328
Apr 2024056
May 2024085
Jun 20240122
Jul 2024090
Aug 20240102
Total019673